StockData

Lisata Therapeutics vs Soligenix

LSTA and SNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LSTA and SNGX compare

Lisata Therapeutics is the larger company, worth 1.6 times as much as Soligenix ($9.8M against $6.3M).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLSTASNGX
Size and price
Market cap$9.8M$6.3M
Share price$1.09$0.288
Change, 1 year−47.3%−79.1%
Change, 5 years−92.6%−99.9%
Beta (5Y)−1.652.34
Employees2114
StockData Score
Total score66
Valuation score11
Growth score00
Performance score00
Health score55
Dividend score00
Valuation
P/S98.2×–
P/B1.2×0.9× (better)
FCF yield−125%–
Growth
Revenue growth (TTM)−90.7%–
Profitability
Operating margin−16427%–
Net margin−14621%–
FCF margin−12323%–
Return on equity−99.9% (better)−242%
Return on invested capital−1645%–
Financial health
Debt / equity0.000.00
Current ratio3.69 (better)2.77
Altman Z-score−74.72−35.07 (better)
Piotroski F-score13 (better)
Dividends and buybacks
Buyback yield−6.0%–
Shareholder yield−6.0%0.00% (better)
Ownership
Held by institutions12.1%4.3%
Held by insiders11.6%0.69%
Short interest, % of float0.43%0.31%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.